Wednesday, 25 Apr 2018

You are here

Favorable Certolizumab Safety Profile in Pregnancy

Clowse and colleagues have published an extensive review of the certolizumab pegol (CZP) in pregnancy database, and found no evidence that CZP has a teratogenic effect or contributes to fetal harm when compared to the general population. 

CZP is a PEGylated, Fc‐free anti‐TNF approved for use in Crohn's disease, rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.  Studies have shown little to no active placental transfer of CZP from the mother to fetus in utero.  Recent studies have also shown no or miniscule levels of CZP in the breast milk of women during lactation.

This report analyzes prospective and retrospective data on maternal CZP exposure from the UCB safety database through March 2017. Analysis was limited to prospective reports to avoid potential bias. 

Of the 1137 maternal CZP‐exposed prospective pregnancies, 528 (including 10 twin pregnancies) had 538 known outcomes: 459 live births (85.3%), 47 miscarriages (8.7%), 27 elective abortions (5.0%), and 5 stillbirths (0.9%).

A total of 8 major congenital malformations (1.7%) were seen in 459 infants.

The vast majority of these exposures were from patients with RA (n=235) or Crohn's disease (n=195) and during the first trimester (81.2%). Nearly half (44.5%) had CZP exposure during all 3 trimesters of pregnancy.

These findings are reassuring for women of childbearing age who are considering treatment with CZP.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Severe Stevens-Johnson and Toxic Epidermal Necrolysis Syndromes May Respond to Etanercept

The Journal of Clinical Investigation reports the results of a trial wherein etanercept (ETN) was shown to be effective in treating cytotoxic T lymphocyte–mediated (CTL-mediated) severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

Pediatric Use of TNF inhbitors Does Not Increase Malignancy Risk

A study of USA administrative claims data between 2000 to 2014 assessed the risk of cancer with exposure to tumour necrosis factor inhibitor (TNFi) in pediatric patients and found that TNFi therapy did not significantly increase the risk compared those not receiving TNFi.

Obesity Outweighs Psoriasis in Comorbidity Risk with Children

Like their adult counterparts, psoriasis in children is an independent risk factor for comorbidity, but not as much as  obesity.

Using claims data from Optum Laboratories Data Warehouse (150 million privately insured and Medicare enrollees), of 29 957 children with psoriasis were matched with a comparator cohort (children without psoriasis) and studied for the effects of psoriasis and obsesity. 

Anti-Drug Antibodies Partly Explain Secondary TNF Inhibitor Failures

An observational study of patients with active rheumatoid arthritis (RA) or spondyloarthritis (SpA) experiencing secondary failure to TNF inhibitor (TNFi) therapy showed that (secondary) loss of efficacy to a TNFi was associated with anti-drug antibodies in less than 30% of patients. 

PRESERVE Study: HAQ, BMI and Age Predict Responses to Combo Therapy

Rheumatoid arthritis patients who were younger and who had lower body mass index, Health Assessment Questionnaire (HAQ) scores, and less disease activity at baseline were most likely to achieve remission after combination etanercept (Enbrel) and methotrexate induction therapy, a post hoc analysis of the PRESERVE trial found.